Recent advances in targeted strategies for triple-negative breast cancer

Table 2 The clinical trials of AR inhibitors in TNBC

Drug name	Com	Num	Regiments	Ph	State	Object	POM	NCT number
Bicalutamide		60	150 mg/d po	II	Unknown	AR⁺TNBC	CBR, PFS	NCT02353988
Bicalutamide		36	150 mg/d po	III	Terminated	AR⁺TNBC	CBR	NCT03055312
Bicalutamide		1	150 mg/d po	II	Terminated	AR⁺TNBC	CBR	NCT02348281
Bicalutamide	Ribociclib	37	Bicalutamide: 150 mg/d po Ribociclib: 400 mg/d po	I/II	Recruiting	AR⁺TNBC	MTD, CBR	NCT03090165
Enzalutamide		50	160 mg/d po for 52 weeks	II	Active, not recruiting	AR⁺TNBC	feasibility	NCT02750358
Enzalutamide	Paclitaxel	37	Enzalutamide: PO daily on days 1–7 Paclitaxel: iv over 2 h on day 1. Treatments repeat every 7 days for up to 12 cycles	II	Recruiting	AR⁺TNBC	pCR	NCT02689427
GTx-024		32	18 mg/d po	II	Terminated	AR⁺TNBC	CBR	NCT02368691
GTx-024	Pembrolizumab	18	GTx-024: 18 mg/d po Pembrolizumab: iv over 30 min on day 1	II	Active, not recruiting	AR⁺TNBC	RR	NCT02971761

AR⁺TNBC: androgen receptor positive triple negative breast cancer; CBR: clinical benefit rate; PFS: progression-free survival; MTD: maximum tolerated dose; pCR: pathologic complete response; RR: response rate

ISSN: 1756-8722